Case Report on Cadonilimab and Chemotherapy for Lung Cancer
Author Information
Author(s): Feng Du, Jiang Huixin, Chen Gengjia, Guan Wenhui, Yi Lin, Zhu Yue, Li Yijia, Huang Gengda, He Bin, Tang Junlong, Tang Yujie, Zeng Jiyuan, Zhou Wensheng, Shi Jiayu, Xie Zhanhong, Liu Ming, Xie Xiaohong, Lin Xinqing, Zhou Chengzhi
Primary Institution: Guangzhou Medical University
Hypothesis
Can combining cadonilimab with chemotherapy improve outcomes for patients with STK11-mutant lung adenocarcinoma?
Conclusion
The combination of cadonilimab and chemotherapy as a first-line treatment showed significant clinical efficacy and safety in a patient with STK11-mutant lung adenocarcinoma.
Supporting Evidence
- The patient achieved a 68% reduction in tumor size after two cycles of treatment.
- Normal levels of tumor markers were observed after treatment.
- The treatment was well-tolerated with no significant adverse events reported.
Takeaway
A patient with lung cancer and a specific gene mutation got better after receiving a new treatment that combines two types of medicine.
Methodology
The patient received cadonilimab with chemotherapy (pemetrexed and carboplatin) and was monitored for tumor response over 12 months.
Limitations
The study lacked direct assessment of PD-1 expression and the functional phenotype of the STK11 mutation in the patient.
Participant Demographics
60-year-old male with advanced lung adenocarcinoma and STK11 mutation.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website